Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

The Effect of COVID Convalescent Plasma on Hospital Stay: A Retrospective Observational Study from a Tertiary Care Hospital in North India

Author(s): Prashant Pandey, Shweta Ranjan, Divya Setya, Supriya Kumari and Saikat Mandal*

Volume 19, Issue 2, 2024

Published on: 10 May, 2023

Page: [95 - 103] Pages: 9

DOI: 10.2174/2772434418666230407133720

Price: $65

Abstract

Introduction: COVID convalescent plasma (CCP) has been used as standard of care in patients all over the world. CCP is plasma collected from recently infected and currently recovered COVID-19 patients, which contains antiviral antibodies that can be used to treat patients with COVID-19. Several studies have shown a shorter hospital stay and lower mortality in patients treated with convalescent plasma in comparison with those not treated with it.

Objectives: This study aims to determine the effect of COVID convalescent plasma (CCP) on the length of hospital stay in symptomatic patients and to determine outcome of the disease in patients who were administered CCP.

Methods: This was a retrospective observational study done at a tertiary health care centre from July 2020 to May 2021, including patients who received CCP during the course of their stay in the hospital.

Results: Among 257 participants, the patients with multiple comorbidities who were administered CCP had the longest average length of stay in the hospital which was 15 days, out of which, 92 (35.8%) patients were discharged while 9 (3.5%) patients died. Also, the maximum number of deaths was observed in those patients who had no associated comorbidity, being 11 (4.3%). It was observed that earlier administration of CCP in patients (< 5 days from symptom onset) was associated with a higher number of discharges as compared to deaths.

Conclusion: Our study indicates that CCP may be efficient in treating COVID-19 patients if given in early course of the disease.

« Previous Next »
Graphical Abstract

[1]
Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130(4): 1545-8.
[http://dx.doi.org/10.1172/JCI138003] [PMID: 32167489]
[2]
Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006; 145(8): 599-609.
[http://dx.doi.org/10.7326/0003-4819-145-8-200610170-00139] [PMID: 16940336]
[3]
Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis 2005; 24(9): 583-91.
[http://dx.doi.org/10.1007/s10096-005-0004-z] [PMID: 16172857]
[4]
Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10(7): 676-8.
[http://dx.doi.org/10.1111/j.1469-0691.2004.00956.x] [PMID: 15214887]
[5]
Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24(1): 44-6.
[http://dx.doi.org/10.1007/s10096-004-1271-9] [PMID: 15616839]
[6]
WHO Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks 2014. http://apps.who.int/iris/rest/bitstreams/604045/retrieve (accessed August 25, 2021)
[7]
Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: A study protocol. Springerplus 2015; 4(1): 709.
[http://dx.doi.org/10.1186/s40064-015-1490-9] [PMID: 26618098]
[8]
Hung IFN, To KKW, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52(4): 447-56.
[http://dx.doi.org/10.1093/cid/ciq106] [PMID: 21248066]
[9]
Food and Drug Administration. Fact sheet for health care providers: Emergency UseAuthorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). 2021. Available at: https://www.fda.gov/media/141478/download
[10]
Department of Health and Family Welfare, Ministry of Health and Family Welfare Government of India https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/ Accessed on 25 Aug 2021.
[11]
Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in COVID-19: Possible mechanisms of action. Autoimmun Rev 2020; 19(7): 102554.
[http://dx.doi.org/10.1016/j.autrev.2020.102554] [PMID: 32380316]
[12]
Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020; 584(7821): 437-42.
[http://dx.doi.org/10.1038/s41586-020-2456-9] [PMID: 32555388]
[13]
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review. J Med Virol 2020; 92(9): 1475-83.
[http://dx.doi.org/10.1002/jmv.25961] [PMID: 32356910]
[14]
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117(17): 9490-6.
[http://dx.doi.org/10.1073/pnas.2004168117] [PMID: 32253318]
[15]
Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience. medrxiv 2020; ; 2020-08.
[http://dx.doi.org/10.1101/2020.08.12.20169359]
[16]
Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis 2020; 222(1): 38-43.
[http://dx.doi.org/10.1093/infdis/jiaa228] [PMID: 32348485]
[17]
Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest 2020; 158(1): e9-e13.
[http://dx.doi.org/10.1016/j.chest.2020.03.039] [PMID: 32243945]
[18]
Budhiraja S, Dewan A, Aggarwal R, et al. Effectiveness of convalescent plasma in Indian patients with COVID-19. Blood Cells Mol Dis 2021; 88: 102548. doi: 10.1016/j.bcmd.2021.102548. Epub2021.
[PMID: 33621948] [PMCID: PMC7891064] [http://dx.doi.org/10.2139/ssrn.3726179]
[19]
Xia X, Li K, Wu L, et al. Improvedclinical symptoms and mortality among patients with severe or critical COVID-19 afterconvalescent plasma transfusion. Blood 2020; 136(6): 755-9. doi:10.1182/blood.2020007079.
[PMID: 32573724] [PMCID: PMC7414593] [http://dx.doi.org/10.1182/blood.2020007079]
[20]
Libster R, Marc PG, Wappner D, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med 2021; 384(7): 610-8.
[http://dx.doi.org/10.1056/NEJMoa2033700] [PMID: 33406353]
[21]
Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apheresis Sci 2020; 59(5): 102875.
[http://dx.doi.org/10.1016/j.transci.2020.102875] [PMID: 32694043]
[22]
Tang J, Grubbs G, Lee Y, Golding H, Khurana S. Impact of convalescent plasma therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody profile in coronavirus disease 2019 (COVID-19) Patients. Clin Infect Dis 2022; 74(2): 327-34.
[http://dx.doi.org/10.1093/cid/ciab317] [PMID: 33861337]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy